Top 3 Australian Founder Led Growth Stocks To Watch In October 2026

Australian investors are watching borrowing costs climb as global bond yields push higher, which puts a premium on companies that can grow under their own steam and have leaders with real skin in the game. That combination can be hard to find. This article looks at fast growing local businesses where insiders hold meaningful stakes and analyst outlooks are upbeat, and highlights 3 stocks from that group that may be worth closer attention.

The three stocks below are just a starting sample from this theme, while the full screen surfaced 112 more companies with similarly compelling stories that are not covered here. To go straight to the full list, analyze insider ownership and growth side by side, and identify your own highest conviction ideas, head into the Fast Growing Stocks With High Insider Ownership screener.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops and commercializes mesenchymal lineage cell therapies aimed at severe inflammatory and cardiovascular diseases using a proprietary platform.

Operations: Mesoblast generates about US$120 million in revenue from developing and commercializing its allogeneic cellular medicines platform.

Market Cap: A$2.6 billion

Mesoblast fits this fast growing, high insider-ownership theme through its late stage regenerative medicine programs that management is actively pushing toward broader commercial use.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

What happens to Mesoblast's future earnings power depends heavily on how one pivotal late stage program reshapes both demand and pricing power.

If that earnings power shift is what you care about, read the full narrative for Mesoblast to see how Mesoblast’s risk, pricing, and adoption story really ties together.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals develops and commercialises radiopharmaceutical imaging agents and cancer therapies, with a strong focus on precision oncology programs.

Operations: Telix generates about US$705 million from Precision Medicine and US$277 million from Manufacturing Solutions, with most revenue from the United States.

Market Cap: A$5.4 billion

Telix Pharmaceuticals fits this fast growing, high insider-ownership theme through its late stage radiopharmaceutical pipeline, where TLX591 and related prostate and kidney cancer programs link directly to clinically focused growth that management keeps putting at the forefront of its story.

"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year."

What happens next for Telix hinges on how one pressure point shapes future pricing power and profitability in its radiopharmaceutical portfolio.

That pricing pressure question is the heart of the full narrative for Telix Pharmaceuticals, which maps where Telix Pharmaceuticals could accelerate, stall, or quietly decouple from peers.

Codan (ASX:CDA)

Overview: Codan designs and sells secure communications systems and metal detectors used by governments, defense agencies, emergency services, and miners worldwide.

Operations: Codan generates about A$506 million from Communications and A$362 million from Metal Detection, with broad exposure across the U.S., Europe, Middle East, and other regions.

Market Cap: A$12.1 billion

Codan fits this fast growing, high insider-ownership theme through its Communications arm, where secure radios and tactical systems aim for long contract cycles with government, defense, and public safety customers that value reliability and service support.

"Heightened geopolitical tensions, increased defense spending, and the need for resilient communications infrastructure, especially in light of remilitarization and growing demand for unmanned systems, are expanding Codan's customer base and forward order book in defense and public safety, driving both near-term and long-term revenue growth."

What happens to Codan’s growth story now depends on how a single pressure point shapes future contract quality, pricing power, and margins.

That contract quality question runs straight into the full narrative for Codan, which weighs Codan’s order book resilience against where margins could quietly accelerate or stall next.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. Breakout themes, rising momentum, and quietly flying under-the-radar stories often get caught late when prices are already dropping. Scan them while it matters and act now.

• Spot income workhorses early by scanning the 6 dividend fortresses, curated for investors who want reliable cash flows while yields still look compelling.
• Hunt for mispriced quality by using the 4 high quality undervalued stocks, built to surface cash generative operators with solid balance sheets before sentiment turns.
• Track the next wave of automation leaders through the 91 robotics and automation stocks, and stay close to businesses building the hardware backbone of tomorrow’s productivity gains.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com